vidofludimus calcium

Immunic’s MS drug shows positive biomarker results in phase 2 trial, boosting investor confidence

Immunic Therapeutics’ strategic decision to refocus its efforts earlier this year appears to be yielding positive results, drawing favorable reactions ...